



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 18th January 2023

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GPwSI in therapeutics
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC

IN ATTENDANCE:

Mr Andrew White	Chief Pharmacist, Lancashire & South Cumbria ICB
Mr Mohammed Fareeth	Acute medicine (ELHT)

2023/01: APOLOGIES:

Mr Chris Woods (CW)	Head of Contracting and Costing, Finance
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes

2023/02: DECLARATION OF INTEREST

SJ declared interest re item 2021/101b

2023/03: MINUTES OF DECEMBER TEAMS MEETING:

Accepted as accurate record.

2023/04: MATTERS ARISING:

2021/101b: ELMMB Membership – to remain on action matrix as a standing item for feedback.

Andrew White, the newly appointed Chief Pharmacist for Lancashire and South Cumbria ICB, introduced himself to group members. **See item 2023/09**



2022/156a: JV Meeting with Mr Hill and lead nurse in Appliance Prescription Service to discuss training/education for team to allow prescribing of product through APS service.

RESOLVED: item closed

2022/180: Expanded Access/Compassionate use schemes in Oncology. Cancer Alliance Chair has emailed to suggest that applications received by ELHT be shared with the Cancer Alliance for the sub-group to review and respond. This will provide equity of treatments across Lancashire and South Cumbria and help to address pressure on pharmacy units. The final decision will still lie with ELMMB group.

RESOLVED: item closed

2022/188: Octreotide: For inclusion on new EoL [Tier 2] palliative care specification across Lancashire and South Cumbria ICS for bowel obstruction, preventing hospital admission. Add to formulary as GREEN restricted for this condition.

RESOLVED: Add to formulary. GREEN restricted Traffic Light

2022/196: Nutritional supplement post-bariatric surgery position statement. Comments fed back to LSCMMG

RESOLVED: item closed

1022/198: Upadictinib financial arrangement for ulcerative colitis (pre-NICE TAG). NICE TA approved.

RESOLVED: item closed

2022/199: Weight management pathways and semaglutide. LR has asked if patients can be referred into the local tier 3 service at Blackpool. The response received has informed LR that the service is for patients referred from the Fylde coast region only. This has been flagged as a commissioning issue with funding restrictions. LR highlighted the inequity of the service across the patch and questioned where the issue could be escalated to in the meantime and whether it would be more appropriate to decommission the service until the matter is resolved. AW reported that the service will be in the tariff for April 23 and advised to refer back into LSCMMG and also raise with the quality committee as an issue.

ACTION: LR to refer back to LSCMMG/quality committee

2023/05: Formulary Updates

a. **Dymista®:** Currently BLACK traffic light on formulary. Request from Dr Corbett to switch to AMBER. This is for a child with severe asthma/allergic rhinitis who is under the care of Manchester Children's Hospital and the family currently have to travel to Manchester for supplies. As this is an individual patient case it was queried if the item could be delivered by Homecare or a paper prescription sent directly to the patient.

ACTION: Not approved. AB to feed back to Dr Corbett

b. **Teriparatide:** request to change from BLACK traffic light to RED for:

- the treatment of osteoporosis in men at an increased risk of fracture



- the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk.

The use of teriparatide for this indication has been endorsed by the National osteoporosis guidelines group. It was agreed to change to RED traffic light for these indications.

Traffic Light RED

- c. **Dapagliflozin:** Approved for treating chronic kidney disease.

Traffic Light GREEN

- d. **Olopatadine hydrochloride and mometasone furoate monohydrate (Ryaltris):** Not approved for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents 12 years of age and older.

Traffic Light BLACK

- e. **Cannabis extract – Delta-9-tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex®) oromucosal spray:** Not approved for refractory neuropathic pain.

Traffic Light BLACK

Resolved: ELMMB formulary will be updated accordingly

2023/06 LSCMMG Consultations – February 2023 [deadline 28/01/23]

- a. **Duloxetine** for Depression and Generalised Anxiety Disorder (RAG change) – currently Amber 0 - proposed **green**
- b. **Tolvaptan** for hyponatremia in adults, secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) – proposed **red**
- c. **Bijuve HRT** – proposed **green restricted**
- d. **Zuclopenthixol decanoate** for the maintenance treatment of schizophrenia and paranoid psychoses – proposed **amber 0**. SJ suggested it would be appropriate, and in line with NICE guidance, for zuclopenthixol decanoate to be amber shared care (amber 1): the guidance indicating initiation in secondary care for 12 months then transferring to primary care under shared care guidance. LR stated that there is no shared care for old antipsychotics and UA suggested that this should be managed the same way as haloperidol. Group agreed with proposed amber 0 proposal

For Action: Comments to be sent to LSCMMG

2023/07 LSCMMG Recommendations–December 2022

- a. Psoriatic Arthritis LSCMMG Recommended Treatment Pathway – Updated
- b. Dementia Medicine Prescribing Information Sheet – Updated
- c. Riluzole Shared Care Guideline – Updated



- d. Riluzole Information Leaflet - Updated

Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2023/08 Pharmacy and Medicines Policy Task and Finish Group recommendations sheet (formally SCC) –December 2022

- a. Dapagliflozin - treating chronic kidney disease- GREEN Traffic Light
- b. Olopatadine hydrochloride and mometasone furoate monohydrate (Ryaltris) - in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis. - BLACK Traffic Light
- c. Cannabis extract – Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex®) oromucosal spray - Refractory neuropathic pain - BLACK Traffic Light

RESOLVED: Website to be updated accordingly.

2023/09 Other Items

Future of ELMMB/D&T Committee:

SJ expressed a declaration of interest as a previous GP clinical lead for ELCCG medicines optimisation and recently holding an interim post as GP clinical lead for the ICB, which terminated at the end of December 2022. She currently holds no official post but explained that is crucial for GPs to have a voice in clinical pathways and prescribing. SJ explained she is happy to continue to represent primary care as an unpaid member if the group was in agreement.

SR asked if there was an update available from AW as we move forward with new structures across the ICB.

AW explained that his role encompasses responsibility for medicines and pharmacy across the ICB. Current financial constraints require consistent high standards, value and equity to be maintained whilst continuing to be safe.

AW considers the current LSCMMG membership to be 'light' on clinical and GP specialists and that it needs to move to a decision-making group across the ICB, offering the consistency that is important to the surrounding footprint e.g. Liverpool, GMMM. By April 2023 it is hoped that a formal group will be in place and will include the appropriate stakeholders. AW is hopeful that moving forward decision-making will be made quicker and more responsive, especially with more clinical input to the group.

VG mentioned that the terms of reference for ELMMB were pertinent to ELHT pathways and will still require primary care representation for assurances for implementation etc and collaborative approach to patient-facing services. VG has drafted new/updated terms of reference for further discussion and will circulate after the meeting.

LR agreed that the TOR need updating to encompass transfer of care, the primary care agenda e.g., hospital specific issues and primary care. It is important that links between primary and secondary care are maintained as we move forward. The current TOR are in line with LSCMMG with a clear flow-chart.

SR commented that LSCMMG often involves an unacceptable delay with the introduction and review of new drugs and makes it distant from clinician practice.



ELMMB captures more local nuances and covers some of the unique requests, including interface, policy operational and medicine optimisation issues

SJ agreed with the need to have a more operational group across the ICB but suggested that there is the need to be able to opt for more slightly different options for a locality. SJ also stressed the need for improved communications to the wider clinical community in both primary and secondary care regarding decisions, updates, changes etc as they are made.

VG expressed a need to address a solution to the possible demise of ELMMB.

ACTION: meeting to be arranged to discuss TOR and governance arrangements for ELHT [LR, VG, AB]. VG to circulate drafted new/updated terms of reference for further discussion.

2023/10 Other Items

Hyperkalaemia ELHT guideline DRAFT & Supporting documentation presented by VG for information only. The documents and draft guideline have been through the medicines safety group and require further update from acute physicians before the final version is available.

Resolved: Item acknowledged and final version to be shared with group. To close item for now.

2023/11 NICE Guidance – December 2022

None

2023/12 NICE Recommendations –December 2022

Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal), not approved for use by **NICE TA848**

Traffic Light: BLACK

Cabozantinib for previously treated advanced hepatocellular carcinoma. Approved in line with **NICE TA849**

NHS England Commissioned

Traffic Light: RED

Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. Not approved by **NICE TA850**

Traffic Light: BLACK

Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. Approved in line **NICE TA851**

NHS England Commissioned

Traffic Light: RED

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. Approved in line with **NICE TA852**

NHS England Commissioned

Traffic Light: RED

Avatrombopag for treating primary chronic immune thrombocytopenia. Approved in line with NICE TA853

ICB Commissioned, Blueteq form required

Traffic Light: RED



Esketamine nasal spray for treatment-resistant depression. Not approved by **NICE**
TA854 **Traffic Light: BLACK**

2023/13 NICE Highly Specialised Technologies – December 2022

None this month

2023/14 EAMS (Early access to medicines scheme) – December 2022

None this month

Resolved: Item acknowledged by ELMMB

Standing Items:

2023/15 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 8th December 2022

Resolved: Minutes acknowledged.

2023/16 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Minutes and open action tracker from Thursday 24th November 2022.

Resolved: Minutes and action tracker acknowledged.

2023/17 For Action/Information: Antimicrobial Stewardship Committee (ASC)

December meeting cancelled. Next meeting 24th January 2023. November 2022 minutes will be available February 2023

Any other Business

Mexiletine capsules: Currently AMBER traffic light on formulary. LSCMMG have recently reviewed the medicine and appointed RED traffic light. There are currently significant price differences between the strengths of mexiletine and following a recent patient safety alert stock is unavailable/in short supply for licensed indications. It was agreed to change the traffic light on ELMMB to RED.

Approved: Mexiletine will be switched to **RED traffic light**

DATE OF NEXT MEETING – Wednesday 22nd February 2023 12.30pm via ‘Microsoft Teams’

(Please note the meeting has been moved forward 1 week to avoid half-term)



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18th January 2023

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that. Await full ICB structure. (see item 2023/09)	LR/VG	Feb 23
2022/156f	Valaciclovir 500mg tablets To remain on formulary, monitor prescribing trend. To be reviewed in June 2023	LR/JV	Jun 23
2022/199	Weight management pathways and semaglutide LR to refer back to LSCMMG	LR	Feb 23
2023/05a	Dymista® Currently BLACK traffic light on formulary. Request from Dr Corbett to switch to AMBER. Not approved. AB to feed back to Dr Corbett	AB	Feb 23
2023/09	Future of ELMMB/D&T Committee Meeting to be arranged to discuss TOR and governance arrangements for ELHT [LR, VG, AB]. VG to circulate drafted new/updated terms of reference for further discussion	LR/VG	Feb 23